|
 |
Prostate Cancer VaccineThis page contains recent news articles, when available, and an overview of Prostate Cancer Vaccine but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.News: Prostate Cancer Vaccine Gaea TimesDendreon Corp. said Friday the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1. ... UPDATE 1-FDA says Dendreon's drug application is complete - Nov 20, 2009 ReutersO) said on Friday that the US Food and Drug Administration has accepted its application to market its experimental prostate cancer vaccine and will rule on ... STOCKS NEWS US-Dell shares plummet after results - Nov 20, 2009 Interactive InvestorAdministration has accepted its application to market its experimental prostate cancer vaccine and will rule on whether to approve it by May 1, 2010. ... BUY OR SELL-US order key for vaccine maker Bavarian Nordic - Nov 12, 2009 ForbesThe 'optimum financial position' comment could be a sign that potential partners for Bavarian Nordic's prostate cancer vaccine, PROSTVAC, might not be as ... UPDATE 1-Dendreon files in U.S. for prostate cancer vaccine - Nov 2, 2009 Reuters IndiaO: Quote, Profile, Research) has completed its US regulatory submission for its closely watched experimental prostate cancer vaccine, the company said on ... Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009 - Nov 12, 2009 PR Newswire (press release)During the first nine months of 2009, Bavarian Nordic reported further confirmatory data on PROSTVAC(TM), the company's late-stage prostate cancer vaccine ... Pharma's big movers: Amylin up on obesity drug, Hep C drug lifts Vertex - Nov 2, 2009 Daily Finance (blog)...on news that company had completed its US regulatory submission for its closely watched experimental prostate cancer vaccine Provenge ahead of schedule. ... Bavarian Nordic A/S - Interim Report for the period 1 January to 30 September 2009 - Nov 11, 2009 Therapeutics Daily (press release) (registration)During the first nine months of 2009, Bavarian Nordic reported further confirmatory data on PROSTVAC(TM), the company's late-stage prostate cancer vaccine ... STOCKS NEWS US-Dow, S&P open higher after Ford results - Nov 2, 2009 Interactive Investor...rose in premarket trading on Monday, after the company said it had completed the US regulatory submission for its experimental prostate cancer vaccine. ... UPDATE 1-Dendreon Q3 loss wider than expected on higher expenses - Nov 9, 2009 Reuters IndiaThe company is developing its experimental prostate cancer vaccine, Provenge, which would be the first "therapeutic" cancer vaccine, if approved. ... Florida leads US in foreclosures - Nov 19, 2009 Palm Beach PostDendreon Corp. said Friday the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1. ... CureVac to start first mRNA prostate cancer vaccine trial - Dec 11, 2008 Pharma Times,CureVac of Germany has announced that the country’s regulatory authority has approved the firm’s clinical trial application to begin a Phase I study of its Provenge Activists Fail To Get FDA Documents - Dec 2, 2008 Pharmalot,...judge has denied a bid to force the FDA to immediately make available documents involved in the controversy over the Provenge prostate-cancer vaccine. Therion Biologics’ cancer vaccine gets a second shot - Oct 28, 2008 Bizjournals.com,News came out earlier this month that the potential prostate cancer vaccine Prostvac, four years after use, led to a statistically significantly longer Provenge Activists Seek US Supreme Court Review - Oct 27, 2008 Pharmalot,...have asked the US Supreme Court to allow them to proceed with a lawsuit against the FDA over its handling of the Provenge prostate cancer vaccine. Uncontrolled Growth - Cancer to Dominate the Global Vaccine Market ... - Oct 31, 2008 PRMinds (press release),Apart from the cervical cancer segment - melanoma, lung lymphoma and prostate cancer vaccine segments are also seeing high activity with a number of Bavarian Nordic A/S (CPH:BAVA) - Interim Report For The Period 1 ... - Nov 3, 2008 ABN Newswire (press release),Our most advanced new product, PROSTVAC(TM) - a late stage prostate cancer vaccine candidate, was acquired as part of a newly established partnership with Cell Genesys Falls 70% as Patient Deaths Derail GVAX Phase III - Aug 27, 2008 BioWorld Online,By Trista Morrison In yet another setback for cancer vaccines, Cell Genesys Inc. terminated one of its two Phase III trials with prostate cancer vaccine Clinical Briefs - Sep 3, 2008 U.S. Medicine,In a previous study involving the same prostate cancer vaccine, IL-2 was given to 19 patients daily for five days during each 28-day vaccine treatment cycle Medical Marketing makes progress in cancer vaccines, says focused ... - Sep 17, 2008 Hemscott,The embattled biotech company said a commercial prostate cancer vaccine, GVX 3322, has been assembled and the DNA sequence verified, following which Cell Genesys drug study gets FDA halt order - Sep 11, 2008 CNNMoney.comInc. said Thursday the Food and Drug Administration placed a partial clinical hold on an ongoing late-stage study for the GVAX prostate cancer vaccine. Beacon Equity Issues Technical Trade Alerts on: CEGE, AMLN - Aug 29, 2008 TransWorldNews (press release),...recently bounced back after dropping 72% to an all-time low Wednesday when the company stopped a clinical trial of its prostate cancer vaccine GVAX. Health Winners & Losers: Amylin - Aug 28, 2008 TheStreet.comCell Genesys(CEGE - Cramer's Take - Stockpickr), which had given up some 75% after it stopped a late stage study on prostate cancer vaccine GVAX on Cell Genesys Sinks To All-Time Low After GVAX Trial Ends Due To ... - Aug 27, 2008 Trading Markets (press release),...(NASDAQ: DNDN), which is developing its own prostate cancer vaccine called Provenge, also declined. The company stopped VITAL-2, one of two late-stage tests Prostate Cancer Vaccine Before Hormones May Boost Survival - Jul 10, 2008 MedPage Today,By Crystal Phend, Staff Writer, MedPage Today BETHESDA, Md., July 10 -- For nonmetastatic castration-resistant prostate cancer, an investigational PROSTATE CANCER, VACCINE, HORMONE THERAPY, CANCER - Jul 9, 2008 Newswise (press release)Newswise — Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival Immune Design Gets $18M for Vaccines and Adjuvants - Jun 23, 2008 TMCnet...s prostate cancer vaccine Provenge (sipuleucel T) have failed to generate sufficiently strong immune responses to meet their endpoints. New prostate cancer vaccine give hope to metastatic prostate ... - May 27, 2008 TopCancerNews.com,A new prostate cancer vaccine may give hope to men with metastatic prostate cancer by enabling their immune systems to fight the disease. Prostate Cancer Vaccine Looks Promising in Early Trial - May 19, 2008 Washington Post,By Steven Reinberg SUNDAY, May 18 (HealthDay News) -- A therapeutic vaccine to treat prostate cancer appears safe and may be effective, according to the UI reports results of prostate cancer vaccine study - May 23, 2008 Iowa City Press Citizen,A team of University of Iowa Health Care researchers is now conducting the next phase of a clinical trial that may eventually lead to new treatments for men Prostate cancer vaccine performs well in early trial - May 22, 2008 FierceBioResearcher,An early-stage trial of an experimental prostate cancer vaccine demonstrated that it was safe and also generated an immune response among a large percentage AUA: Prostate Cancer Vaccine Linked to Improved Survival in Small ... - May 19, 2008 MedPage Today,By Charles Bankhead, Staff Writer, MedPage Today ORLANDO, May 19 -- More than half of men with metastatic, hormone-refractory prostate cancer had New Prostate Cancer Vaccine to Save Lives - May 15, 2008 Keep the Doctor Away,Scientists have done what was previously thought to be impossible and launched a new prostate cancer vaccine, which could finally give hope to men with New way to fight cancer tested - May 19, 2008 Ocala.com,Vieweg brought his studies of the potential prostate cancer vaccine with him from Duke University when he joined the UF College of Medicine faculty in 2006. Scientists find new cancer vaccine target - May 23, 2008 InTheNews.co.uk,Russia for its kidney cancer vaccine Oncophage – a world first - while Dendreon is still trying to get US approval for its prostate cancer vaccine Provenge. ALSO NOTED: FDA, Medicare team up on drug surveillance; Early ... - May 23, 2008 FierceBiotech,Report > An early-stage trial of an experimental prostate cancer vaccine demonstrated that it was safe and also generated an immune response among a large Global market expected to drive cancer drug growth - May 14, 2008 The Associated PressLast year, the agency denied approval of Dendreon's prostate cancer vaccine Provenge, despite an overwhelmingly positive review by the agency's outside Therapeutic DNA Vaccine Company Inovio Biomedical Reports First ... - May 9, 2008 WELT ONLINE,Third, the University of Southampton presented interim data from its phase I/II clinical study of an experimental DNA-based prostate cancer vaccine, Daiichi Sankyo to Purchase German Biotech for $235M - May 21, 2008 BioWorld Online,...worldwide licensing deal with South San Francisco-based Cell Genesys Inc. for its GVAX prostate cancer vaccine and plans to acquire Cambridge, Mass. Cell Genesys Issues Stock in Private Placement - May 12, 2008 TheStreet.comCell Genesys will use the net proceeds to fund product development, including some of the phase III costs for its prostate cancer vaccine GVAX, Takeda, US Firm Partner To Develop Prostate Cancer Vaccine - Apr 1, 2008 Therapeutics Daily (subscription) (press release),...biomedicine firm Cell Genesys Inc. announced Tuesday that they have teamed up to develop and commercialize Cell Genesys' prostate cancer vaccine, GVAX. Cuba Studies Candidate Prostate Cancer Vaccine - Mar 31, 2008 Cuba News,Camaguey, Cuba, March 31 (acn) A Cuban candidate vaccine against prostate cancer, produced by the Genetic Engineering and Biotechnology Center in this Prostate Cancer DNA Vaccine Results in Higher T-Cell Response When ... - Apr 4, 2008 Business Wire (press release),...of an experimental DNA-based prostate cancer vaccine at the American Association for Cancer Research meeting in San Diego, USA, April 12 – 16, 2008. Biz Break: Drug pact could earn Cell Genesys $320 million - Apr 1, 2008 San Jose Mercury News,...of South San Francisco $50 million now and up to $270 million more later for the right to co-develop Cell Genesys' prospective prostate-cancer vaccine. Buyout or Sellout? - Apr 18, 2008 Motley Fool...(Nasdaq: AMGN) and licensing rights for some of its cancer drugs; and join Cell Genesys to develop and market the company's prostate cancer vaccine. Millennium Pharma Soars on Takeda Bid - Apr 10, 2008 The Associated PressOther deals for Takeda include rights to market Cell Genesys Inc.'s prostate cancer vaccine. Millennium's key drug is the blood cancer treatment Velcade, Takeda Bids $8.8B for US' Millennium - Apr 10, 2008 The Associated PressTakeda also landed right to develop and globally market Cell Genesys Inc.'s prostate cancer vaccine The cash offer is worth $25 per share, more than a 50 Florist questioned over deliveries to FDA office - Apr 15, 2008 Business Gazette,...were sent to commemorate the one-year anniversary of two FDA advisory panel votes recommending the agency approve Provenge, a prostate cancer vaccine. Japan's Takeda Will Pay $9B for Millennium - Apr 10, 2008 TheStreet.comTakeda also signed a worldwide partnership with Cell GenesysCEGE for that company's experimental prostate cancer vaccine. For Millennium, the Takeda UPDATE 1-Dendreon sees $47 mln gross proceeds from offering - Apr 3, 2008 ReutersDendreon said it would use net proceeds to fund activities related to its prostate cancer vaccine, Provenge, which is still waiting for marketing approval NEWS | SAN DIEGO Inovio Biomedical product tests safe - Apr 4, 2008 San Diego Daily Transcript (subscription),...will present interim data from a clinical study of an experimental DNA-based prostate cancer vaccine at a meeting in San Diego on April 12. Japanese drugmaker Takeda to buy Millennium Pharmaceuticals for US ... - Apr 10, 2008 PR-Inside.com (Pressemitteilung),Takeda also got an exclusive right to develop and globally market Cell Genesys Inc.'s prostate cancer vaccine. Takeda said Millennium's key product, Takeda Offers $8.8 billion for Biotech Millennium - Apr 10, 2008 International Business Times,It also bought Abbott Laboratories and the license to develop and sell a prostate cancer vaccine from Cell Genesys Inc. Background information on Prostate Cancer Vaccine [When available] [an error occurred while processing this directive] Search the web for more resources on Prostate Cancer Vaccine |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
